United Therapeutics chairperson & CEO sells $4.7m in stock

Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corp., sold 9,500 shares of the company's common stock on September 22, 2026, for $4,700,850. The sales were carried out under a pre-arranged 10b5-1 trading plan and followed the vesting of stock options. Despite this, the company reported mixed quarterly results, with earnings per share exceeding expectations but revenue falling short of projections.

United Therapeutics' stock currently trades at $475.45, with a market capitalization of $20.39 billion, and analysts suggest it may be overvalued. BofA Securities lowered its price target to $559 with a Neutral rating, while Goldman Sachs initiated coverage with a Sell rating and a $321 target, citing valuation concerns.